



We claim:


1. A compound selected from
a compound of formula 1:




a compound of formula 2:



a compound of formula 3:



a compound of formula 4:




4

,

and pharmaceutically acceptable salts thereof.

2. A compound selected from a compound of formula 1:




1

,

and pharmaceutically acceptable salts thereof.

3. A compound selected from a compound of formula 2:




2

,


and pharmaceutically acceptable salts thereof.

4. A compound selected from a compound of formula 3:



and pharmaceutically acceptable salts thereof.

5. A compound selected from a compound of formula 4:



and pharmaceutically acceptable salts thereof.


6. The compound of claim 1, wherein said compound is stereomerically pure.
7. The compound of claim 1, wherein said compound comprises greater than about 80% by weight of one stereoisomer of the compound.

8. The compound of claim 1, wherein said compound comprises greater than about 90% by weight of one stereoisomer of the compound.
9. The compound of claim 1, wherein said compound comprises greater than about 95% by weight of one stereoisomer of the compound.
10. The compound of claim 1, wherein said compound comprises greater than about 97% by weight of one stereoisomer of the compound.
11. A pharmaceutical composition comprising a compound and/or pharmaceutically acceptable salt thereof according to any one of claims 1-10.
12. The pharmaceutical composition of claim 11, wherein said composition is formulated for intravenous, oral, subcutaneous, or intramuscular administration.
13. The pharmaceutical composition of claim 12, wherein said composition is formulated for oral administration.
14. The use of the compound or pharmaceutically acceptable salt thereof according to any one of claims 1-10, or the pharmaceutical composition according to any one of claims 11-13, in the preparation of a medicament for the treatment of a cancer selected from myelodysplastic syndrome, chronic lymphocytic leukemia, acute lymphoblastic leukemia, chronic myelomonocytic leukemia, acute myeloid leukemia, colon cancer, pancreatic cancer, endometrial cancer, ovarian cancer, breast cancer, uveal melanoma, gastric cancer, cholangiocarcinoma, and lung cancer.

15. The use of claim 14, wherein said cancer is colon cancer.
16. The use of claim 14, wherein said cancer is pancreatic cancer.
17. The use of claim 14, wherein said cancer is selected from myelodysplastic syndrome, chronic lymphocytic leukemia, acute lymphoblastic leukemia, chronic myelomonocytic leukemia, and acute myeloid leukemia.
18. The use of claim 14, wherein said cancer is acute myeloid leukemia.
19. The use of claim 14, wherein said cancer is myelodysplastic syndrome.
20. The use of claim 14, wherein said cancer is chronic lymphocytic leukemia.
21. The use of claim 14, wherein said cancer is acute lymphoblastic leukemia.
22. The use of claim 14, wherein said cancer is chronic myelomonocytic leukemia.
23. The use of claim 14, wherein said cancer is endometrial cancer.
24. The use of claim 14, wherein said cancer is ovarian cancer.
25. The use of claim 14, wherein said cancer is breast cancer.
26. The use of claim 14, wherein said cancer is uveal melanoma.

27. The use of claim 14, wherein said cancer is gastric cancer.
28. The use of claim 14, wherein said cancer is cholangiocarcinoma.
29. The use of claim 14, wherein said cancer is lung cancer.
30. The use of any one of claims 14-29, wherein said cancer is positive for one or more mutations in a spliceosome gene or protein.
31. The use of claim 30, wherein said spliceosome gene or protein is selected from splicing factor 3B subunit 1 (SF3B1), U2 small nuclear RNA auxiliary factor 1 (U2AF1), serine/arginine-rich splicing factor 2 (SRSF2), zinc finger (CCCH type) RNA-binding motif and serine/arginine rich 2 (ZRSR2), pre-mRNA-processing-splicing factor 8 (PRPF8), U2 small nuclear RNA auxiliary factor 2 (U2AF2), splicing factor 1 (SF1), splicing factor 3a subunit 1 (SF3A1), PRP40 pre-mRNA processing factor 40 homolog B (PRPF40B), RNA binding motif protein 10 (RBM10), poly(rC) binding protein 1 (PCBP1), crooked neck pre-mRNA splicing factor 1 (CRNKL1), DEAH (Asp-Glu-Ala-His) box helicase 9 (DHX9), peptidyl-prolyl cis-trans isomerase-like 2 (PPIL2), RNA binding motif protein 22 (RBM22), small nuclear ribonucleoprotein Sm D3 (SNRPD3), probable ATP-dependent RNA helicase DDX5 (DDX5), pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15 (DHX15), and polyadenylate-binding protein 1 (PABPC1).
32. The use of claim 31, wherein said spliceosome gene or protein is splicing factor 3B subunit 1 (SF3B1).

33. A pharmaceutical composition comprising a compound selected from a compound of formula 2:



2

and pharmaceutically acceptable salts thereof.

34. The pharmaceutical composition of claim 33, wherein said composition is formulated for intravenous, oral, subcutaneous, or intramuscular administration.

35. The pharmaceutical composition of claim 34, wherein said composition is formulated for oral administration.

36. The use of a pharmaceutical composition of any one of claims 33-35 in the preparation of a medicament for the treatment of a cancer selected from myelodysplastic syndrome, chronic lymphocytic leukemia, acute lymphoblastic leukemia, chronic myelomonocytic leukemia, acute myeloid leukemia, colon cancer, pancreatic cancer, endometrial cancer, ovarian cancer, breast cancer, uveal melanoma, gastric cancer, cholangiocarcinoma, and lung cancer.

37. The use of claim 36, wherein said cancer is colon cancer.

38. The use of claim 36, wherein said cancer is pancreatic cancer.

39. The use of claim 36, wherein said cancer is selected from myelodysplastic syndrome, chronic lymphocytic leukemia, acute lymphoblastic leukemia, chronic myelomonocytic leukemia, and acute myeloid leukemia.

40. The use of claim 36, wherein said cancer is acute myeloid leukemia.

41. The use of claim 36, wherein said cancer is myelodysplastic syndrome.

42. The use of claim 36, wherein said cancer is chronic lymphocytic leukemia.

43. The use of claim 36, wherein said cancer is acute lymphoblastic leukemia.

44. The use of claim 36, wherein said cancer is chronic myelomonocytic leukemia.

45. The use of claim 36, wherein said cancer is endometrial cancer.

46. The use of claim 36, wherein said cancer is ovarian cancer.

47. The use of claim 36, wherein said cancer is breast cancer.

48. The use of claim 36, wherein said cancer is uveal melanoma.

49. The use of claim 36, wherein said cancer is gastric cancer.

50. The use of claim 36, wherein said cancer is cholangiocarcinoma.

51. The use of claim 36, wherein said cancer is lung cancer.

52. The use of any one of claims 36-51, wherein said cancer is positive for one or more mutations in a spliceosome gene or protein.

53. The use of claim 52, wherein said spliceosome gene or protein is selected from splicing factor 3B subunit 1 (SF3B1), U2 small nuclear RNA auxiliary factor 1 (U2AF1), serine/arginine-rich splicing factor 2 (SRSF2), zinc finger (CCCH type) RNA-binding motif and serine/arginine rich 2 (ZRSR2), pre-mRNA-processing-splicing factor 8 (PRPF8), U2 small nuclear RNA auxiliary factor 2 (U2AF2), splicing factor 1 (SF1), splicing factor 3a subunit 1 (SF3A1), PRP40 pre-mRNA processing factor 40 homolog B (PRPF40B), RNA binding motif protein 10 (RBM10), poly(rC) binding protein 1 (PCBP1), crooked neck pre-mRNA splicing factor 1 (CRNKL1), DEAH (Asp-Glu-Ala-His) box helicase 9 (DHX9), peptidyl-prolyl cis-trans isomerase-like 2 (PPIL2), RNA binding motif protein 22 (RBM22), small nuclear ribonucleoprotein Sm D3 (SNRPD3), probable ATP-dependent RNA helicase DDX5 (DDX5), pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15 (DHX15), and polyadenylate-binding protein 1 (PABPC1).

54. The use of claim 53, wherein said spliceosome gene or protein is splicing factor 3B subunit 1 (SF3B1).